Since their discovery as key mediators of cytokine signaling, considerable progress has been made in de®ning the structure-function relationships of Signal Transducers and Activators of Transcription (STATs). In addition to their central roles in normal cell signaling, recent studies have demonstrated that diverse oncoproteins can activate speci®c STATs (particularly Stat3 and Stat5) and that constitutively-activated STAT signaling directly contributes to oncogenesis. Furthermore, extensive surveys of primary tumors and cell lines derived from tumors indicate that inappropriate activation of speci®c STATs occurs with surprisingly high frequency in a wide variety of human cancers. Together, these ®ndings provide compelling evidence that aberrant STAT activation associated with oncogenesis is not merely adventitious but instead contributes to the process of malignant transformation. These studies are beginning to reveal the molecular mechanisms leading to STAT activation in the context of oncogenesis, and candidate genes regulated by STATs that may contribute to oncogenesis are being identi®ed. Recent studies suggest that activated STAT signaling participates in oncogenesis by stimulating cell proliferation and preventing apoptosis. This review presents the evidence for critical roles of STATs in oncogenesis and discusses the potential for development of novel cancer therapies based on mechanistic understanding of STAT signaling.
Introduction
Delineation of cytokine signaling pathways that control cellular growth, dierentiation, survival and development has de®ned a novel class of proteins known as STATs that regulate these processes by modulating the expression of speci®c target genes (for an overview of STATs, see Bromberg and Darnell, this issue) . STAT proteins are activated by cytokine engagement of cognate cell surface receptors and induce the expression of ligand-dependent genetic programs that determine the biological response to the stimulus. Although originally discovered as eectors of normal cytokine signaling, subsequent studies have demonstrated the participation of STATs in signaling by polypeptide growth factors and oncoproteins. Precise regulation of STAT activation is critical with regard to eliciting the appropriate responses to extracellular signals. In the event that control of STAT activation is deregulated, for example through constitutive ligand/receptor engagement or oncogenic tyrosine kinase (TK) activity, aberrant STAT signaling may contribute to malignant transformation by promoting cell cycle progression and/or cell survival. Because STATs directly regulate gene expression, implicit in the constitutive activation of STATs observed during oncogenesis is the acquisition of a permanent alteration in the genetic program. Moreover, better understanding of the mechanisms underlying aberrant STAT signaling during oncogensis may lead to the development of novel cancer therapies based on interrupting key steps in this pathway. In this review, we summarize the mechanisms involved in STAT activation in the context of oncogenesis, and discuss the consequences of inappropriate STAT activation in malignant transformation.
Activation of STATs in normal signal transduction
Studies of interferon-dependent gene expression led to the recognition that STAT proteins are signaling molecules with dual functions Stark et al., 1998) . STAT proteins not only transmit a signal from the cell surface to the nucleus but also directly participate in gene regulation Ihle et al., 1995) . Further studies revealed that STAT proteins are involved in signaling by many cytokines, such as IL-6 family cytokines (Hirano et al., 1997; Taga and Kishimoto, 1997) , and numerous growth factors, including EGF and PDGF (Leaman et al., 1996; Schindler and Darnell, 1995) . Seven mammalian STAT family members (Stat1 ± Stat6, with Stat5A and Stat5B encoded in distinct genes) have been molecularly cloned and likely represent the entire complement of STATs in mammalian cells . Figure 1 depicts the major structural features of STAT proteins. The C-terminal portion of STATs contains several key elements required for STAT activation and function (Shuai et al., 1994; Wen and Darnell, 1997; Wen et al., 1995) . The Src-homology 2 (SH2) domain is a common structural motif among signaling molecules that mediates protein-protein interactions via direct binding to speci®c phosphotyrosines. Phosphorylation of a critical tyrosine residue activates STATs by stabilizing the association of two STAT monomers through reciprocal phosphotyrosine-SH2 interactions to form a dimer. The extreme Cterminal region of STATs contains the transactivation domain that is required for transcriptional activation. In addition to activation by tyrosine phosphorylation, phosphorylation of a serine residue in the transactivation domain of some STATs (particularly Stat1 and Stat3) contributes to maximal transcriptional activity . Naturally-occurring splice variants of STATs such as Stat1b and Stat3b, which lack the C-terminal transactivation domain and this serine residue, can often block the function of the full-length proteins (or a forms) in a dominantnegative manner (Bromberg et al., 1996; Caldenhoven et al., 1996) . In the N-terminal portion, STATs contain the DNA-binding domain and a region that mediates oligomerization between two STAT dimers bound to DNA (Horvath et al., 1995; Xu et al., 1996) .
The following description and Figure 2 brie¯y illustrate the mechanism of STAT activation in normal signal transduction Darnell et al., 1994) . Signaling initiates when ligands such as cytokines bind to and activate their cell surface receptors, typically by inducing receptor aggregation. Cytokine receptors such as the interferon or IL-6 receptors, which lack intrinsic TK activity, recruit members of the Janus kinase (JAK) family of cytoplasmic TKs to act as intermediaries for activation of STATs (Ihle, 1996; Ihle et al., 1995) . The JAK family consists of Jak1, Jak2, Jak3 and Tyk2, each of which may be activated by a variety of receptors. Following ligand engagement, the receptor-associated JAKs become activated by phosphorylating themselves and subsequently phosphorylate tyrosine residues within the receptor cytoplasmic tails. The receptor phosphotyrosines serve as docking sites for recruitment of inactive cytoplasmic STAT monomers through interaction with the SH2 domain in STATs. JAKmediated phosphorylation of an invariant tyrosine residue on the receptor-bound STAT monomer induces the phosphorylated STAT monomers to associate with each other through interaction of the phosphotyrosine of one molecule with the SH2 domain of another molecule, as described above. The activated dimers then translocate to the nucleus, where they bind to speci®c DNA-response elements (Seidel et al., 1995) in the promoters of target genes and thereby induce unique gene expression programs.
In contrast to typical cytokine receptor signaling, activated growth factor receptors with intrinsic TK Figure 1 Structures of STAT proteins. Shown are the major structural features and their functions in the known mammalian STAT proteins. The N-terminal oligomerization region is involved in stabilizing interactions between two STAT dimers bound to adjacent sites in DNA. The DNA-binding domain directly contacts DNA and confers speci®city of binding to palindromic sequences in promoters of genes. Located between the oligomerization region and the DNA-binding domain is a region of helical coils involved in interactions with other proteins important in transcriptional regulation. Phosphorylation of the invariant tyrosine (Y) residue in the dimerization region mediates interaction with the SH2 domain of another monomer that stabilizes STAT dimer formation. The C-terminal transactivation domain is involved in transcriptional activation of STATregulated genes. Located within the transactivation domain of some STAT proteins is a critical serine (S) residue that is required for maximal transcriptional activity. Shown are two naturallyoccurring splice variants of Stat1 and Stat3, denoted as Stat1b and Stat3b, which have deletions within this transactivation domain. The closely related Stat5A and Stat5B proteins are encoded in distinct genes Figure 2 Mechanisms of STAT signaling. Shown are examples of dierent tyrosine kinase (TK) signaling pathways that can induce activation of STAT proteins. In the case of cytokines like IL-6 that bind to receptors lacking intrinsic TK activity, ligandinduced dimerization of the receptor (R) results in phosphorylation and activation of receptor-associated JAK family kinases. The activated JAKs in turn phosphorylate the receptor cytoplasmic tails on tyrosine, providing docking sites for recruitment of monomeric STATs. JAKs then phosphorylate the recruited STAT proteins on tyrosine, inducing dimerization, nuclear translocation, and DNA-binding activity. In some cases, other TKs such as SRC family kinases are also involved in cytokine-induced STAT activation. In the case of growth factors like EGF that bind to receptor tyrosine kinases (RTKs), the receptor can directly phosphorylate STATs and/or indirectly induce STAT phosphorylation through activation of intermediary kinases of the SRC and JAK families. In addition, non-receptor TKs such as activated SRC and ABL can directly phosphorylate STAT proteins in the absence of ligand-induced receptor signaling. Activation of TK signaling pathways often leads to simultaneous activation of serine/threonine kinases, including p38, JNK and ERK, which phosphorylate STATs on serine (S) residues in the C-terminal transactivation domain. Once in the nucleus, activated STAT proteins bind to speci®c DNA sequences in the promoters of genes and induce their expression through interactions with other transcriptional regulatory components. In the context of oncogenesis, constitutive activation of TK-STAT signaling pathways induces elevated expression of genes involved in controlling fundamental cellular processes such as cell proliferation and survival Oncogene STATs in oncogenesis T Bowman et al activity, e.g. EGF receptor and PDGF receptor, may directly phosphorylate STAT proteins (Figure 2 ). In addition to growth factor receptors and JAKs, other TKs that directly phosphorylate STATs are cytoplasmic kinases such as Src and Abl. For example, c-Src is involved in STAT activation by the IL-3 receptor, EGF and PDGF receptors (Chaturvedi et al., 1997 (Chaturvedi et al., , 1998 Olayioye et al., 1999; Wang et al., 2000) . Thus, depending on the particular receptor and cellular context, dierent TKs are involved in activation of STAT signaling by both cytokine and growth factor receptors. For this reason, STAT signaling pathways might be more appropriately called`TK-STAT' pathways. What determines which TK is involved in STAT activation by a given receptor, and why in some cases more than one TK appears to be involved, are questions that remain to be answered. One possibility is that the use of dierent TKs allows the simultaneous coupling of receptors to dierent combinations of signaling pathways that determine particular biological responses.
Control of normal biological processes by STATs
Activation of STATs results in expression of genes that control critical cellular functions including cell proliferation, survival, dierentiation and development, as well as specialized cellular functions such as those associated with immune responses. Although the STAT family is highly structurally conserved, there are distinct dierences both in primary sequence and in function. The contribution of speci®c STAT family members to control of normal cellular processes has been elucidated based on studies of homozygous deletion or more recently, by tissue-speci®c, conditional knockout of each STAT family member in mice (Akira, 1999) . Stat1-de®cient mice are impaired in their ability to respond to interferons and become susceptible to infections from bacterial and viral pathogens (Durbin et al., 1996; Meraz et al., 1996) . Targeted disruption of the Stat4 Thierfelder et al., 1996) or Stat6 (Shimoda et al., 1996; Takeda et al., 1996; Thierfelder et al., 1996) gene in mice demonstrates that these STATs are required for IL-12-or IL-4-induced proliferation of activated T lymphocytes, respectively.
Although the Stat5A and Stat5B genes are highly related, both at the genetic and protein levels, targeted disruption of either gene exhibits a tissue-speci®c phenotype with respect to each gene. Stat5A knockout mice display defects in mammary gland development and lactation during pregnancy (Liu et al., 1997) , while Stat5B knockout mice display sexually dimorphic patterns of liver gene expression (Udy et al., 1997) . Female mice lacking functional Stat5A and Stat5B proteins are infertile and a role for Stat5 proteins in proper immune function has also been demonstrated in the double-knockout animals (Teglund et al., 1998) .
In the case of Stat2 (Kimura et al., 1996) and Stat3 (Takeda et al., 1997) , homozygous deletion of the gene encoding either protein is embryonic lethal, indicating a critical role for each in normal development. Due to the limitations imposed by Stat3-null animals, i.e. mortality at day 6.5 to 7 during early development, investigators have recently created tissue-speci®c, Stat3-null conditions using the Cre-Lox system. Analysis of mice lacking Stat3 expression in keratinocytes demonstrates a role for Stat3 signaling in control of cell motogenesis as it pertains to wound healing (Sano et al., 1999) . Furthermore, in contrast to wild-type littermates, IL-6 fails to prevent apoptosis in T lymphocytes from mice de®cient for Stat3 signaling (Takeda et al., 1998) . Thus, from the above studies it is clear that STAT proteins are required for regulation of many diverse cellular functions. Future studies using tissue-speci®c STAT knockout animals will undoubtedly contribute to further elucidating the roles of STATs as they pertain to normal signaling.
Activation of STATs by oncogenic tyrosine kinases
Over the past two decades, progress on the cellular mechanisms that contribute to oncogenesis has evolved from the identi®cation of viral and cellular oncoproteins that transform mammalian cells to de®nition of the signaling pathways that are disrupted during oncogenesis. Subversion of a cell's normal genetic program results in alterations in the expression patterns of genes involved in dierent facets of transformation, such as cell proliferation, anchorageindependent growth, survival, and morphological changes. These and other hallmarks of transformation are now being understood on a molecular level by functional analyses of key signaling components and their contribution to neoplastic transformation. In contrast to normal signaling, in which STAT activation is rapid yet transient, constitutive signaling by STATs has been increasingly associated with malignant progression. Because activation of STAT proteins requires tyrosine phosphorylation, and for some STAT family members serine phosphorylation, identi®cation of the kinases that are responsible for catalyzing STAT phosphorylation has yielded valuable insight into the molecular mechanisms involved in activation of STATs in human tumors.
JAK family kinases
The ®rst genetic evidence implicating constitutive STAT activation in oncogenesis was derived from studies of signal transduction in fruit¯ies. A lethal gain-of-function mutation induces hyperactive TK activity in the Drosophila JAK homolog, hopscotch (Harrison et al., 1995; Luo et al., 1995) . As a result, fruit¯ies expressing the constitutively-activated JAK develop a hematopoietic neoplasia resembling leukemia. Dominant suppressors of this phenotype map to loss-of-function mutations in the Drosophila homolog of a mammalian STAT gene (Hou et al., 1996; . Thus, these studies suggest that deregulated JAK kinase activity, inducing constitutive activation of a Drosophila STAT, directly leads to the formation of hematopoietic malignancies in fruit¯ies. Moreover, since Drosophila STAT is homologous with mammalian Stat5, the results obtained in fruit¯ies presaged the contribution of STATs to human cancer.
Involvement of aberrant JAK activation in human cancer is linked to a chromosomal abnormality in acute lymphocytic leukemia (ALL). Chromosomal translocation of the short arm of chromosome 9, containing the kinase domain of Jak2, to the short arm of chromosome 12, containing the oligomerization domain of the Ets transcription factor, results in a fusion protein (Tel-Jak2) possessing constitutive kinase activity (Ho et al., 1999; Lacronique et al., 1997) . Enforced dimerization due to the contribution from the Ets portion of the molecule mimics cytokine-induced activation of Jak2 at membrane-bound receptors. Subsequent studies demonstrated that introduction of the Tel-Jak2 fusion protein into hematopoietic cell lines results in constitutive activation of Stat1, Stat3, and Stat5 and induces factor-independent proliferation (Schwaller et al., 1998) . Furthermore, mice harboring cells that express Tel-Jak2 develop fatal myelo-and lympho-proliferative diseases.
Src family kinases
In mammalian cells, the original report demonstrating that STATs are constitutively activated in cells stably transformed by a speci®c oncoprotein linked activation of the oncogenic Src tyrosine kinase to activation of one STAT family member, Stat3 (Yu et al., 1995) . These studies demonstrated that an excellent correlation exists between activation of Stat3 and oncogenic transformation by Src. This observation, which was con®rmed and extended by other investigators (Cao et al., 1996; Chaturvedi et al., 1997) , raised the possibility that diverse oncoproteins of the receptor or non-receptor TK family may also activate STATs during oncogenic transformation. Srcfamily members and related kinases such as Lck and v-Fps have been reported to activate STATs Lund et al., 1997; Nelson et al., 1998; . In T cells expressing a herpesvirus saimiri protein (Tip-484) required for transformation of T cells, activation of Lck by Tip-484 induces constitutive activation of Stat1 and Stat3 (Lund et al., 1999a,b) . In addition, v-Src activates Stat3 in cell lines derived from human gall bladder adenocarcinomas (Murakami et al., 1998) and mammary epithelial cells (Smith and Crompton, 1998) . In NIH3T3 cells, Jak1 and to a lesser extent Jak2 are constitutively activated by v-Src (Campbell et al., 1997) . Furthermore, recent studies indicate that Jak1 and v-Src cooperate in the activation of Stat3 in transformed NIH3T3 cells . These latter studies support a model in which Jak1 serves to recruit Stat3 to Src, which in turn directly phosphorylates and activates Stat3.
Signi®cantly, two reports provided the ®rst evidence that constitutive STAT activation by an oncoprotein directly participates in transformation (Bromberg et al., 1998b; Turkson et al., 1998) . These studies demonstrated that constitutive Stat3 DNA-binding activity induced by the Src oncoprotein results in stimulation of Stat3-dependent gene expression. Moreover, abrogation of Stat3 signaling by co-expression of dominant-negative forms of the Stat3 protein blocks the transforming ability of Src (Bromberg et al., 1998b; Turkson et al., 1998) . In contrast, coexpression of dominant-negative Stat3 together with the Ras oncoprotein, which does not activate Stat3 , does not block Ras-induced transformation. The combined results of these studies demonstrate that constitutive activation of Stat3 signaling is one pathway required for cellular transformation by speci®c classes of oncoproteins like Src possessing TK activity. While Stat3 is almost certainly only one of probably many signaling pathways required for transformation by the Src oncoprotein, it is signi®cant that disruption of this pathway is sucient to block cell transformation. These studies suggest that activated Stat3 signaling contributes to oncogenesis by eliciting permanent changes in the genetic program required for the initiation and/or maintenance of transformation. Interestingly, dominant-negative Stat3 protein appears to block Src transformation by inducing cell cycle arrest and apoptosis, suggesting that activated Stat3 signaling contributes to transformation of these cells by promoting cell proliferation and preventing cell death (T Bowman and R Jove, unpublished). This conclusion is consistent with ®ndings that candidate genes regulated by Stat3 in the context of oncogenesis are involved in controlling cell growth and survival, as described later.
Abl family kinases
Pre-B lymphocytes transformed by the oncogenic TK, v-Abl, possess constitutively activated Stat1 and Stat5 (Danial et al., 1995) . Constitutive activation of STATs by v-Abl appears to involve JAKs, since both Jak1 and Jak3 are activated in these cells. Indeed, recent studies indicate that activation of Jak1 is required for STAT activation by v-Abl via a direct, physical association between v-Abl and Jak1 (Danial et al., 1998) . Moreover, pre-B cell lines expressing a mutant v-Abl protein lacking the Jak1 interaction domain or defective for Jak1 signaling fail to support factorindependent growth or induce tumors in mice. In contrast, the oncogenic fusion protein, BCR-Abl, has been shown to activate Stat1 and Stat5 in hematopoietic cell lines in the absence of constitutive JAK activation (Carlesso et al., 1996; Chai et al., 1997; Frank and Varticovski, 1996; Ilaria and Van Etten, 1996; Shuai et al., 1996) , indicating a divergence in the mechanisms of STAT activation between v-Abl and BCR-Abl. Importantly, using dominant-negative and constitutively-activated Stat5 proteins, the activation of Stat5 has been shown to be essential for transformation by BCR-Abl (de Groot et al., 1999; Nieborowska-Skorska et al., 1999) .
Other oncoproteins
The prediction that diverse oncoproteins may contribute to oncogenesis by activating speci®c STAT family members Yu et al., 1995) has been borne out in numerous studies. Table 1 lists the viral and cellular oncogenes that are known to activate speci®c STAT family members. Oncoproteins such as v-Sis, v-Fps , v-Ros, insulin-like growth factor I (IGF-I) receptor (Zong et al., 1998) , and c-Eyk/v-Eyk (Besser et al., 1999; Zong et al., 1996) have been shown to activate predominantly Stat3 in ®broblast cell lines and to a lesser extent Stat1. In epithelial cells, the cellular tyrosine kinase, Etk/BMX, is able to activate Stat1, Stat3 and Stat5 (Wen et al., 1999) . The pro®le of STATs activated by a given oncoprotein may depend to some degree on the speci®city of the oncoprotein as well as cell type. It is likely that the list of oncoproteins that activate STAT signaling will continue to grow, especially among oncoproteins that directly or indirectly induce tyrosine kinase signaling.
Despite the ®nding that Stat1 is sometimes activated in conjunction with Stat3 or Stat5, it appears unlikely that Stat1 contributes to oncogenesis. The evidence accumulated to date favors the interpretation that Stat1 is predominantly growth inhibitory, consistent with the anti-proliferative response to interferon-g, which activates exclusively Stat1 (Bromberg et al., 1996 (Bromberg et al., , 1998a Buard et al., 1998; Chin et al., 1996; Grimley et al., 1998; Xu et al., 1998) . In addition, mice with homozygous deletion of Stat1 are predisposed to certain malignancies and develop tumors with more rapid frequency and kinetics than their wild-type littermates (Kaplan et al., 1998) , suggesting that Stat1 may actually have tumor suppressor functions. Moreover, p53-null mice that are defective for Stat1 signaling develop a broader tumor spectrum than their p53-null counterparts, suggesting that loss of Stat1 signaling further enhances oncogenesis (Kaplan et al., 1998) . Thus, activation of Stat1 in response to signaling by cytokines, such as IFN-g, appears to be critical for mediating growth inhibition. This raises the question as to why Stat1 activation does not prevent oncogenesis in transformed cells where its activation is detected. One possibility is that the growth inhibitory eects of activated Stat1 can be overcome by the simultaneous activation of Stat3 or Stat5, which often accompanies Stat1 activation in oncogenesis. In this scenario, the pro-proliferative activities of Stat3 and Stat5 would predominate over the anti-proliferative activity of Stat1.
Serine phosphorylation of STATs
Concurrent induction of multiple signaling pathways occurs in response to stimulation by growth factors or oncoproteins, allowing coordination of signaling functions and the possibility of complex regulation by cross-talk among signaling pathways. Tyrosine phosphorylation of STATs constitutes an early event in the activation of these transcription factors that is required for their dimerization and DNA-binding activity. In addition, phosphorylation of a serine residue in the C-terminal transcriptional activation domain, corresponding to Ser-727 in both Stat1 and Stat3 (Figure 1 ), enhances the transcriptional activity of these STATs (Wen and Darnell, 1997; Wen et al., 1995) . This transcriptional enhancement involves mechanisms that are not fully understood but may include favorable interactions between STATs and co-activator proteins (Decker and Kovarik, 1999) . The implications of this feature of STAT regulation are that both tyrosine and serine phosphorylations are essential for full activation of STAT signaling, and that STATs are points of convergence for tyrosine and serine kinases (Beadling et al., 1996; Ng and Cantrell, 1997; Wen et al., 1995) . In contrast to the more well-characterized events of STAT activation by tyrosine phosphorylation, however, regulation of STATs by serine phosphorylation is understood less.
MAPK and PKC family kinases
Numerous studies suggest that members of the mitogen-activated protein kinases (MAPK) family (Schaeer and Weber, 1999), including extracellular signal-regulated kinases (ERKs) (Chung et al., 1997; David et al., 1995; Kuroki and O'Flaherty, 1999; Ng and Cantrell, 1997) , c-Jun N-terminal kinase (JNK) (Lim and Cao, 1999; Turkson et al., 1999) and p38 mapk (p38) (Gollob et al., 1999; Turkson et al., 1999) , participate in the serine phosphorylation of Stat1 and Stat3 (Figure 2) . Furthermore, there is evidence for a role of protein kinase C (PKC) in serine phosphorylation of STATs (Jain et al., 1999) . Also implicated in STAT serine phosphorylation are two unde®ned serine kinases, an H7-sensitive serine kinase (Boulton et al., 1995; van Puijenbroek et al., 1999) , and MAPK kinase (MKK)-dependent, ERK-independent serine kinases (Ceresa et al., 1997; Chung et al., 1997) . Direct phosphorylation of Stat3 or Stat1 in vitro by ERKs (Chung et al., 1997) , p38 and JNK (Turkson et al., 1999) provides evidence that members of the MAPK family can induce STAT serine phosphorylation and regulate their activity in vivo. It is also relevant that the site of serine phosphorylation in both Stat3 and Stat1, -Pro-Met-Ser-Pro-, complies with the MAPK consensus sequence, -Pro-X-Ser/(Thr)-Pro- (Alvarez et al., 1991; Schaeer and Weber, 1999) . Presumably, the relative contribution of each of these serine kinases to STAT signaling in vivo would depend on a variety of factors, including cell-type speci®c expression of the serine kinases and their interactions with individual STAT members.
Complexity of STAT serine phosphorylation
It is now becoming clear that regulation of STAT function by serine phosphorylation is more complex than originally expected. In addition to enhanced transcriptional activity induced by serine phosphorylation, repression of STAT signaling has also been associated with serine phosphorylation events under certain conditions. Several mechanisms have been proposed for this negative regulation: (1) an apparent direct in¯uence of serine phosphorylation on preventing STAT tyrosine phosphorylation (Chung et al., 1997) ; (2) indirect eects due to preferential association of STAT proteins with the serine kinases, precluding interaction with tyrosine kinases (Jain et al., 1998 (Jain et al., , 1999 Lim and Cao, 1999) ; (3) a negative feedback eect of the serine kinase on an upstream protein tyrosine kinase (Sengupta et al., 1998) . One can envision a negative feedback mechanism in which serine phosphorylation of STATs promotes the induction of physiologic inhibitors of STAT signaling, such as those of the Suppressor of Cytokine Signaling (SOCS) family that inhibit at the level of JAKs (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997) . A seemingly dual functional role is thus implied for STAT serine phosphorylation events, whereby the same serine kinases can apparently both enhance and repress STAT signaling. Noteworthy, however, is the`superactive' states of the serine kinases that are present in some of the studies where negative regulation of STATs by serine phosphorylation is observed (Jain et al., 1998) . These ®ndings are consistent with recent results indicating that moderate levels of ERKs enhance, while overexpression of ERKs inhibits, Stat3 transcriptional activity (Turkson et al., 1999) . Clearly, more work needs to be done to de®ne mechanisms by which serine phosphorylation regulates the activation and functions of STAT proteins.
STAT serine phosphorylation in oncogenesis
Given that Stat3 serine phosphorylation is required for maximal activation of Stat3 signaling, it is predicted that tyrosine phosphorylation is not sucient for the obligatory role of Stat3 signaling in Src oncogenesis (Bromberg et al., 1998b; Turkson et al., 1998) . Indeed, the contribution of serine phosphorylation of STATs to oncogenesis is becoming increasingly evident. Earlier reports of constitutive serine phosphorylation of Stat1 and Stat3 in human tumors, including leukemias (Frank et al., 1997) and lymphomas (Nielsen et al., 1997; Zhang et al., 1996) , suggested that serine phosphorylation participates in STAT signaling during oncogenesis. Direct support for this assertion comes from the ®nding that a dominant-negative Stat3 mutant with a Ser-727 to Ala-727 mutation, which blocks serine phosphorylation, suppresses Stat3 signaling and Src transformation (Bromberg et al., 1998b) . This observation was more recently con®rmed in studies showing that blocking the serine kinase signaling pathways leading to induction of Stat3 serine phosphorylation also blocks Stat3 signaling and Src transformation (Turkson et al., 1999) . The signaling pathways leading to Stat3 serine phosphorylation in Src oncogenesis were recently delineated and observed to be Ras-dependent (Turkson et al., 1999) , consistent with an essential role for Ras in Src transformation (Stacey et al., 1991) . Through use of both genetic and pharmacological approaches, it was determined that p38 and JNK are key serine kinases that mediate Stat3 serine phosphorylation in the context of Src transformation (Turkson et al., 1999) . Importantly, inhibition of p38 activity blocks constitutive Stat3 serine phosphorylation and transcriptional activity, as well as Src transformation (Turkson et al., 1999) . These observations demonstrate a convergence on Stat3 of tyrosine and serine kinase signaling pathways that have an essential role in oncogenesis by the Src oncoprotein. Similar to the wide-spread involvement of Stat3 tyrosine phosphorylation in a variety of human tumors, it appears likely that further investigation will reveal a wider role of constitutive Stat3 serine phosphorylation in malignant transformation.
Constitutively activated mutants of STATs
Importantly, studies utilizing mutations of STATs, rendering them constitutively active by various mechanisms, demonstrate that constitutive activation of STAT signaling is sucient to induce at least some aspects of cell transformation. Mutations introduced into Stat5 generate a constitutively activated form that, when expressed in an IL-3-dependent mouse pre-B cell line, induces factor-independent proliferation (Onishi et al., 1998) . Acquisition of IL-3-independent proliferation in this cell line suggests that Stat5 may contribute to oncogenesis by promoting cell cycle progression and/or survival. A more recent report demonstrates that the constitutive Stat5 mutant induces expression of Bcl-x L and Pim-1, suggesting that these and other Stat5-dependent gene products contribute to factorindependent growth and survival (Nosaka et al., 1999) . In contrast, a constitutively-activated mutant form of Stat3, expressed in murine macrophages, mimics one of the eects of IL-10 by inhibiting proliferation but fails to suppress macrophage activation (O'Farrell et al., 1998) . Thus, constitutive activation of this particular Stat3 mutant replaces some but not all of the functions of IL-10 cytokine signaling, and suggests that cell-type speci®city and/or tissue-speci®c context plays a key role in determining the biological outcome of aberrant STAT signaling.
Signi®cantly, a recent study provides the ®rst genetic evidence that Stat3 possesses intrinsic oncogenic potential in the absence of upstream TK activating events . A constitutivelyactivated Stat3 molecule (Stat3-C) was genetically engineered that is capable of dimerization in the absence of tyrosine phosphorylation. As a result of this enforced dimerization, Stat3-C homodimers migrate to the nucleus, bind to Stat3 response elements in promoters and induce gene expression. Moreover, rodent ®broblast cells expressing Stat3-C form colonies in soft agar and induce tumors in nude mice . Thus, constitutive activation of Stat3 DNA-binding leads to induction of a Stat3-dependent genetic program that is sucient to recapitulate some hallmarks of cell transformation in the absence of other signaling pathways that might be activated by TKs. This ®nding provides further evidence for the causal role of constitutively-activated Stat3 signaling in oncogenesis, as opposed to being merely an adventitious event resulting from phosphorylation by promiscuous TKs. The identi®cation of STAT-regulated genes, discussed below, will be important in further de®ning the underlying mechanisms of neoplastic transformation resulting from constitutive STAT signaling.
Target genes regulated by STATs
Signal transduction often involves the transmission of a stimulus from the cell surface to the nucleus such that speci®c genetic programs are induced that allow the cell to respond appropriately to the stimulus. In normal cells, these signal transduction mechanisms are tightly controlled to prevent unscheduled gene regulation and consequently inappropriate biological responses. In contrast, constitutive STAT-dependent gene expression may contribute to oncogenesis by inducing elevated expression of key gene products required to initiate and/or maintain transformation. While the identi®cation of STAT-regulated genes is currently under intense investigation, there are a number of candidate target genes that have already been characterized. The genes discussed below have all been associated with oncogenesis through regulation of cell cycle progression and/or apoptosis, implicating a direct role for STATs in mediating transformation through induction of genes critical for these processes.
Bcl-x L
From studies utilizing the constitutively-activated form of Stat3, Stat3-C, several key Stat3-regulated genes have been identi®ed. Expression of Stat3-C induces transcription of reporter constructs containing promoter sequences derived from the bcl-x gene . A strong correlation exists between elevated levels of members of the Bcl-2 family of anti-apoptotic regulatory proteins, including Bcl-x L protein, and human cancer (Reed, 1999) . Signi®cantly, in a human myeloma cell line dependent on IL-6 for survival, constitutive Stat3 activation directly contributes to induction of bcl-x gene expression (Catlett-Falcone et al., 1999a,b) . Furthermore, functional disruption of IL-6 mediated Stat3 signaling in these tumor cells inhibits bcl-x expression, correlating with induction of apoptosis. Consistent with these results, studies with TK inhibitors in NIH3T3 cells expressing v-Src indicate that the bcl-x gene is induced by v-Src in a Stat3-dependent manner (Karni et al., 1999) . The expression of another member of the Bcl-2 family, Mcl-1, has recently been shown to be dependent on Stat3 activation in multiple myeloma and large granular lymphocyte (LGL) leukemia (Epling-Burnette et al., 2000; Puthier et al., 1999) . In addition, activation of Stat5 signaling in response to various cytokines such as IL-3 (Dumon et al., 1999) or erythropoietin (EPO) (Silva et al., 1999) is required for maximal expression of Bcl-x L and correlates with cell survival. Moreover, Stat5 signaling has recently been shown to be required for the survival of EPO-dependent red blood cell precursors (Socolovsky et al., 1999) . Mice nullizygous for both Stat5A and Stat5B suer fetal anemia due to increased apoptosis of erythroid precursors, correlating with decreased expression of Bcl-x L protein. Consistent with these ®ndings, recent studies demonstrate that Stat5 contributes to the induction of bcl-x gene expression by BCR-Abl (de Groot et al., 2000) . Together, these ®ndings provide compelling evidence that constitutively-activated STAT signaling, particularly involving Stat3 and Stat5, contributes to malignant progression by preventing apoptosis.
Cyclin D1
Alteration in the expression levels of proteins required for regulating transit through the cell cycle has been detected in numerous human malignancies. Precise control of cell cycle progression depends on formation and activation of speci®c cyclin/cyclin-dependent kinase (CDK) complexes at de®ned points within the cell cycle (Sherr and Roberts, 1999). The expression of cyclin D1, which associates with cdk4 or cdk6 and controls progression from G1 to S phase, is elevated in Stat3-C expressing cells . Since Stat3-C possesses oncogenic potential, it is possible that Stat3-mediated transcriptional regulation of key components of cell cycle control contributes to malignant progression by promoting inappropriate cell cycle traversal. Consistent with this possibility, cyclin D1 mRNA and protein levels are elevated in NIH3T3 ®broblast cells stably transformed by the v-Src oncoprotein compared to their normal counterparts (Sinibaldi et al., 2000) . Moreover, v-Src-induced Stat3 activation results in expression of a cyclin D1 promoter-based reporter, which is blocked by coexpression of a Stat3 dominant-negative protein. In addition, regulation of the cyclin D1 gene by Stat5 has also been observed (de Groot et al., 2000; Matsumura et al., 1999; Wen et al., 1999) . Thus, activation of the two STAT family members most strongly associated with oncogenesis, Stat3 and Stat5, results in increased expression of a critical regulator of cell cycle progression. These ®ndings are consistent with the suggestion that inappropriate STAT activation contributes to oncogenesis by stimulating cell proliferation.
p21 WAF1/CIP1
It has been previously shown that Stat1 activation in response to interferon-g results in induction of p21 WAF1/CIP1 and growth arrest (Bromberg et al., 1996; Chin et al., 1996) . The p21 WAF1/CIP1 promoter contains three STAT binding sites, two of which bind Stat1 and one that binds Stat1 and Stat3 (Chin et al., 1996) . In NIH3T3 ®broblasts stably transformed by the v-Src oncoprotein and harboring activated Stat3, p21 WAF1/CIP1 mRNA and protein levels are increased compared to non-transformed ®broblasts (Sinibaldi et al., 2000) . As observed for cyclin D1, Stat3 activation by v-Src induces expression of a p21 WAF1/CIP1 promoter-based reporter, while co-expression of a Stat3 dominantnegative protein blocks this induction. Although increases in p21 WAF1/CIP1 levels are normally associated with cell cycle arrest, a number of studies have also reported elevated levels of p21 WAF1/CIP1 in human tumors (Barboule et al., 1998; Kuwahara et al., 1999; Pindzola et al., 1998; Sparrow et al., 1998) . This apparent contradiction in p21 WAF1/CIP1 function may be explained by the ®nding that, in addition to its growth inhibitory role, p21 WAF1/CIP1 also performs an essential scaolding function to promote the assembly of active cyclin D1/CDK complexes (LaBaer et al., 1997) . Thus, in Src-transformed cells that proliferate more rapidly than their normal counterparts, the observed coordinate increases in p21 WAF1/CIP1 and cyclin D1 expression may be essential for stimulating cell cycle progression.
c-Myc
The c-myc gene is over-expressed or ampli®ed in a number of human malignancies (Dang et al., 1999) . Itself a transcription factor, c-Myc protein is a critical regulator of both cell proliferation and survival. Endogenous c-myc mRNA levels are elevated in rodent ®broblast cell lines stably expressing Stat3-C, implicating a role for Stat3 in regulating c-myc expression either directly or indirectly . Consistent with this ®nding, c-myc expression is induced in Src-transformed NIH3T3 cells, although the precise role of Stat3 in regulation of cmyc by Src remains to be determined (T Bowman, J Turkson, N Sinibaldi, R Croxton, D Cress and R Jove, unpublished data). Furthermore, in the context of mitogenic responses to growth factors like PDGF and EGF, transcriptional regulation of c-myc appears to be mediated by Src family kinases through a Rasindependent pathway (Barone and Courtneidge, 1995) . Recent studies demonstrate that Stat3 mediates transcriptional regulation of the c-myc gene in response to IL-6 (Kiuchi et al., 1999) . Mutation of a consensus Stat3-binding site within the c-myc promoter abolishes IL-6-induced transcription of reporter constructs. In addition, using dierential display screening of gene expression in a murine pre-B cell line, a recent report demonstrates that the pim-1 gene is upregulated in response to gp130-mediated signaling (Shirogane et al., 1999) . The pim-1 gene is a protooncogene encoding a serine/threonine kinase associated with various murine lymphoid malignancies (Breuer et al., 1989a,b; Cuypers et al., 1984; van Lohuizen et al., 1989 van Lohuizen et al., , 1991 . In murine pre-B cells defective for Stat3 signaling, co-expression of pim-1 and c-myc is sucient to rescue cells from a block in G1 to S phase cell cycle progression and prevent apoptosis (Shirogane et al., 1999) .
From the above studies, it is clear that Stat3 and Stat5 regulate multiple cellular genes that could contribute to oncogenesis by mechanisms that include promotion of cell cycle progression and prevention of apoptosis. However, it is likely that there are other genes regulated by STATs that may also contribute to oncogenesis, and identi®cation of such genes is the focus of ongoing studies.
Activation of STATs in human cancer
Four major ®ndings, discussed above, have identi®ed STATs as critical mediators of oncogenic signaling and have led to the hypothesis that constitutive activation of STAT proteins may participate in development and progression of human tumors: (1) STATs are selectively activated by oncogenic tyrosine kinase signaling pathways; (2) dominantnegative STAT mutants block STAT-dependent transcription and transformation induced by activated TKs; (3) constitutively-activated mutants of STATs can induce some aspects of cell transformation; and (4) inappropriate activation of STATs in oncogenesis leads to induction of genes involved in controlling cell proliferation and survival. In further support of the critical role of STATs in oncogenesis, Table 2 lists the many dierent human tumor types for which elevated STAT DNA-binding activity has been detected in both tumor cell lines and primary tumor specimens. While Stat1 is also activated in some tumors, it is likely the major STATs involved in promoting oncogenesis are Stat3 and Stat5, for the reasons discussed earlier. These ®ndings are consistent with critical roles for activated STAT signaling in malignant progression of human tumors, including various blood malignancies and solid tumors, some of which are discussed in more detail below.
Leukemias/lymphomas
Activation of speci®c JAKs and STATs has been demonstrated in various human blood malignancies, including lymphomas and leukemias (Migone et al., 1995; Gouilleux-Gruart et al., 1996; Zhang et al., 1996) . As discussed above, transient activation of STATs is critical to transmission of cytokine-induced proliferative, dierentiation and survival signals in hematopoietic cell types. Under normal circumstances, ligand availability and negative feedback pathways tightly regulate cytokine-induced activation of STATs. A number of studies suggest that the constitutive activation of STATs in transformed hematopoietic cells is associated with a permanent alteration in gene expression pro®les that mimics cytokine-induced signaling and leads to ligand-independent expansion and/or survival of these cells. For example, in the myeloid cell line 32D c13, transformation by the v-Src oncoprotein results in abrogation of G-CSF-induced granulocyte dierentiation and engraftment of v-Src-transformed cells induces tumors in nude mice (Kruger and Anderson, 1991) . Subsequent studies suggest that abrogation of IL-3 growth dependence and G-CSF-induced dierentiation is dependent on constitutive activation of STATs by vSrc (Chaturvedi et al., 1997 (Chaturvedi et al., , 1998 . Constitutive activation of STATs 1 and 5 has been detected in acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) cells possessing the activated BCR-Abl tyrosine kinase (Chai et al., 1997; Frank and Varticovski, 1996; Ilaria and Van Etten, 1996; Skorski et al., 1998) . Constitutive STAT activation in these cells mimics many aspects of IL-3-induced signaling such as mitogenesis and enhanced survival (Carlesso et al., 1996) and plays important roles in malignant transformation (de Groot et al., 1999; Nieborowska-Skorska et al., 1999) . Activation of STATs has also been detected in various lymphomas and in multiple myeloma cells (discussed below) and appears to have similar roles in modulation of cytokine-independent growth and malignant transformation of these cell types.
Multiple myeloma
Previous studies have established the critical role of IL-6 in proliferation and survival of human multiple myeloma cells (Hallek et al., 1998; Kishimoto et al., 1994) . Furthermore, IL-6 has been shown to induce activation of Stat3 and to up-regulate the antiapoptotic protein Bcl-x L (Kishimoto et al., 1994; Schwarze and Hawley, 1995) . The model human myeloma cell line, U266, possesses constitutivelyactivated Stat3, as do the majority of bone marrow tumor specimens from multiple myeloma patients (Catlett-Falcone et al., 1999a,b) . Using speci®c inhibitors, abrogation of IL-6 receptor-mediated signaling, inactivation of JAK family kinases, or inhibition of Stat3 transcriptional activity were shown to decrease Bcl-x L mRNA and protein levels and induce apoptosis in U266 cells (Catlett-Falcone et al., 1999b) . Conversely, ectopic overexpression of Bcl-x L rescues U266 cells from apoptosis induced by blocking this signaling pathway, providing evidence that Bcl-x L contributes to the anti-apoptotic eect of Stat3 signaling . Furthermore, inhibition of Stat3 signaling in primary cultures of human myeloma cells from patient bone marrows blocks expression of Bcl-x L and induces apoptosis, suggesting that the mechanisms delineated in model U266 cells re¯ect those in actual tumors (L Moscinski, B Hill, M Huang, T Landowski, M Oshiro, W Dalton and R Jove, unpublished). Thus, in human myeloma cells, Stat3 activation is essential for Lymphoma ( transduction of signals generated from the IL-6 receptor that result in increased cell survival, consistent with earlier results in murine pre-B cells (Fukada et al., 1996) . These ®ndings provide evidence that, by preventing apoptosis, Stat3 activation may be a critical event involved in the accumulation of long-lived myeloma cells during progression of disease. Furthermore, these studies indicate that multiple myeloma provides a useful and relevant model for investigating the role of cytokine-mediated Stat3 signaling in human cancer.
Head and neck squamous cell carcinoma
Constitutive activation of STATs has been detected in extracts from human head and neck squamous carcinoma cells (Grandis et al., 1998) . In these cells, activation of STATs is dependent on TGF-a induced activation of the EGF receptor tyrosine kinase. Signi®cantly, studies utilizing antisense oligonucleotides have demonstrated that Stat3, but not Stat1, mediates TGF-a induced oncogenic growth of these cells (Grandis et al., 1998) . These ®ndings suggest that constitutive activation of Stat3 may also be critical to development and progression of human tumors possessing activated growth factor receptor signaling pathways. Similar to multiple myeloma, these studies further indicate that head and neck squamous cell carcinoma is a useful and relevant human tumor model for investigating the roles of Stat3 in TGF-a and EGF receptor mediated oncogenesis.
Breast cancer
Aberrantly elevated expression and/or activity of EGF receptor family kinases, particularly HER1/erbB-1 and HER2/neu, and aberrant expression of EGF-family ligands have been associated with the progression of human breast cancer (Khazaie et al., 1993) . In addition, activation of c-Src also occurs with elevated frequency during progression of human breast cancer (OttenhoKal et al., 1992) and has been associated with constitutive activation of HER1 and HER2 proteins (Luttrell et al., 1994; Muthuswamy and Muller, 1995) . EGF receptor and c-Src have been previously shown to cooperate in mitogenesis and transformation of model cell lines (Maa et al., 1995) . Signi®cantly, constitutive activation of Stat3 has been detected in human breast carcinoma cell lines but not in mammary epithelial cell lines established from non-malignant tissues Sartor et al., 1997) . Constitutive Stat3 activation in human breast cancer cells correlates with elevated EGF receptor and c-Src expression or activity . Activation of Stat3, and to some extent Stat1, has been detected in primary breast tumor specimens compared to adjacent non-malignant tissue (J Bromberg and J Darnell, unpublished data; P Chaturvedi and EP Reddy, unpublished data) . Activation of STATs appears to be associated with malignant transformation and is not found in benign lesions (R Garcia and R Jove, unpublished data) . Furthermore, constitutive activation of STATs is also detected in tumor-in®ltrated lymph nodes, suggesting it may be a property of more invasive tumor cells. Using speci®c TK-selective inhibitors, inhibition of signaling downstream of Src or JAKs was shown to abrogate constitutive Stat3 DNA-binding, inhibit cell proliferation and induce apoptosis in model human breast carcinoma cell lines . Moreover, expression of dominant-negative Stat3 in these cells induces growth arrest and apoptosis (R Garcia, G Niu, H Yu and R Jove, unpublished data 
Other solid tumors
More recently, constitutive activation of STATs has also been detected in a wide diversity of primary tumors and cell lines derived from human tumors, including various prostate, renal cell, lung, ovarian, and pancreatic cancers as well as melanomas (refer to Table 2 ). Activation of STATs in lung cancer cells has been shown to be dependent on signaling by the HER2/neu receptor tyrosine kinase (Fernandes et al., 1999) . The signaling pathways responsible for STAT activation in the other tumor types have not been well characterized and are currently under investigation. It is likely that at least some of the mechanisms responsible for aberrant STAT activation in the various model transformed cell lines and human tumors described above will be functional in other solid tumor types as well. Thus, present evidence suggests that activated STAT signaling may participate in the development and progression of many dierent types of human blood malignancies and solid tumors.
STATs as markers of oncogenic transformation
Despite the diversity in oncogenic signals and the variety of tumor cell types involved, tumor cells harboring activated TKs acquire similar patterns of STAT activation, particularly involving Stat3 and Stat5. These ®ndings suggest that the development of assays for detection of activated STATs may be useful in the diagnosis of human cancer. Speci®cally, activated STATs may provide a sensitive marker for detecting activation of oncogenic signaling pathways and aid in the selection of treatment modalities that may result in more ecient eradication of disease. Assays designed to detect STATs in their`activated' states may include DNA-binding assays based on microplate assays that measure the relative levels of STAT-DNA complexes by colorimetric detection. Furthermore, antibodies designed to detect the activated phosphotyrosine forms of speci®c STAT family members can be employed to compare normal and tumor tissues by immunohistochemistry for nuclear localization and levels of activated STATs. Another useful application of STAT assays could be to provide a convenient molecular endpoint for monitoring the eectiveness of tyrosine kinase inhibitors that are currently being tested or developed for clinical trials. In addition, the critical role of STATs in oncogenic signal transduction may provide the basis for development of novel cancer therapeutics, as discussed below.
Strategies for targeting STATs for cancer therapy
The implication of the studies discussed above is that aberrant STAT signaling contributes to a permanent alteration in the genetic program of cells that ultimately results in malignant progression. Because STAT proteins are involved in regulating fundamental biological processes, including apoptosis and cell proliferation, disruption of STAT signal transduction is a novel approach to blocking malignant progression in a wide variety of human tumors whose growth depends on activation of STATs. There are multiple strategies that can be taken to design inhibitors that disrupt STAT signaling. One approach involves identi®cation of upstream STAT activators and design of pharmacologic inhibitors that speci®cally disrupt their function. Examples of such upstream targets are cytokines, growth factors, TKs and serine kinases to which antagonists and inhibitors can be synthesized (refer to Figure 2 ). Alternatively, a more direct approach is the rational design of small molecules that directly target STAT proteins and disrupt their function.
Indirect approaches to blocking STAT activation
Autocrine and paracrine activation of cytokine receptors participates in the progression of numerous hematologic and non-hematologic malignancies. One consequence of constitutive cytokine receptor activation is deregulation of STAT signaling. For example, malignant progression of multiple myeloma depends on the IL-6 signaling pathway for growth and survival (Keller and Ershler, 1995; Suematsu et al., 1992) . Molecular modeling of IL-6 interaction with the gp130 subunit of the IL-6 receptor has generated novel superantagonists' that have been shown to be eective in blocking IL-6 receptor activation (Savino et al., 1994) . For instance, using a human myeloma model, an IL-6 superantagonist results in signi®cant reduction in Stat3 DNA-binding and inhibits proliferation Catlett-Falcone et al., 1999a,b) . Table 1 lists the variety of oncoproteins that have been discovered thus far to constitutively activate STAT family members in transformed cell lines. Overexpression and/or elevated kinase activity of Src, BCR-Abl, JAKs, IGF-I receptor, EGF receptor and other cellular TKs are associated with numerous human malignancies shown in Table 2 . Thus, identi®-cation of the TKs and serine kinases that activate speci®c STAT family members provides the basis for development of another class of inhibitors of STAT signaling. Tyrphostins, compounds that selectively inhibit TK activities, have been shown to be therapeutically successful in several recent studies (Levitzki, 1999) . For example, in a model of human acute lymphocytic leukemia (ALL), the tyrphostin AG490 inhibited proliferation of ALL cells in mice without adverse eects on normal hematopoiesis (Meydan et al., 1996) . Moreover, AG490 blocks activation of Stat3 DNA-binding and inhibits proliferation in model human and mouse myeloma cells by inducing apoptosis (Burdelya et al., 2000; CatlettFalcone et al., 1999b) . Other examples include TK inhibitors that selectively target the EGF receptor and Src family kinases and thus may block tumor cell growth through similar mechanisms involving inhibition of Stat3 signaling (Fry et al., 1994; Kraker et al., 2000) . Another TK inhibitor, which is selective for the BCR-Abl kinase and is predicted to inhibit Stat5 signaling, shows promise for treatment of CML patients (Druker et al., 1996) .
In addition, elevated serine kinase activity is associated with oncogenesis (Frank, 1999) , and increased levels of serine phosphorylation of Stat1 and Stat3 have been detected in chronic lymphocytic leukemia (CLL) (Frank et al., 1997) . Moreover, blocking serine phosphorylation of Stat3 in ®broblast cells transformed by the Src oncoprotein inhibits their growth in soft agar (Turkson et al., 1999) , suggesting that serine kinases may possess potential as promising chemotherapeutic targets. Additional therapeutic strategies might be based on modulation of biological suppressors of STAT signaling, including the SH2 domain-containing tyrosine phosphatase family (SHP-1 and SHP-2) (Kharitonenkov et al., 1997; Stofega et al., 1998; Yu et al., 2000) , the SOCS/JAB/SSI family of JAK regulators (Endo et al., 1997; Naka et al., 1997; Starr et al. 1997) , the PIAS family of STAT regulators , and degradation of STATs by proteasomes ) (reviewed in Naka et al., 1999; Starr and Hilton, 1999) .
Methods to directly block STAT function
Detailed structure-function relationships of STAT proteins have been elucidated based on genetic, biochemical and crystallographic analyses, facilitating the design of compounds that directly disrupt STAT function. For example, one potential structural element against which to design selective inhibitors of STAT function is the phosphotyrosine-SH2 interaction domain (refer to Figure 1 ). Peptidomimetics that disrupt the association of STAT SH2 domains with phosphotyrosines may inhibit STAT recruitment to receptors and STAT dimerization, thereby blocking nuclear translocation and STAT-dependent gene regulation. Molecular modeling studies based on the crystal structures of activated STAT proteins bound to DNA could provide promising leads for design of novel STAT inhibitors (Becker et al., 1998; Chen et al., 1998) .
Another potential functional domain by which to modulate the eects of STAT activation is the DNAbinding domain. Small molecule inhibitors that directly interfere with the STAT DNA-binding domain or oligodeoxynucleotide (ODN) strategies utilizing decoy STAT consensus binding sites may prevent activated STATs from inducing transcription of target genes. One therapeutic approach involves the use of STAT anti-sense ODNs that speci®cally block expression of STAT mRNA transcripts. In a recent study, introduction of anti-sense Stat3 ODNs into human head and neck squamous carcinoma cell lines inhibits proliferation in vitro and correlates with loss of Stat3 DNA-binding (Grandis et al., 1998) , suggesting that in vivo delivery of anti-sense STAT ODNs is a potentially promising anti-cancer therapy.
Compounds that interfere with STAT functions such as dimerization, DNA-binding or transcriptional activation can be screened utilizing high-throughput assays based on inhibition of these STAT biochemical properties. In addition, the ecacy and cytotoxicity of these compounds can be evaluated utilizing cultured human tumor cells and in vivo animal models. Initial studies utilizing normal mouse ®broblasts demonstrate that disrupting Stat3 signaling is not deleterious to normal cell growth (Niu et al., 1999; Turkson et al., 1998) . Thus, blocking Stat3 signaling may not grossly impair normal cellular functions. One possible explanation for the increased sensitivity of transformed cells compared to normal cells is that tumor cells may have become irreversibly dependent on STAT signaling to sustain their growth and survival, while normal cells may be able to use alternative pathways to compensate for loss of STAT signaling.
Although gene therapy approaches to cancer treatment are still in relatively early stages of development, gene therapy oers a powerful experimental tool to establish`proof-of-principal' that a particular molecular pathway is a valid target for cancer treatment. Using a mouse melanoma cell line harboring constitutively-activated Stat3, a recent study employed a gene therapy technique with a dominant-negative form of Stat3 to block endogenous Stat3 signaling (Niu et al., 1999) . Syngeneic mice with tumors induced by the melanoma cell line were electroinjected intratumorally with a vector expressing the dominant-negative Stat3 or empty vector. Tumor regression due to massive apoptosis in vivo occurred in mice that received dominant-negative Stat3, in contrast to those that received empty vector (Niu et al., 1999) . Interestingly, the number of apoptotic cells appeared to greatly exceed the number of transfected cells, suggesting that a`bystander' eect may enhance the therapeutic potential of this approach. These ®ndings are consistent with earlier observations that blocking Stat3 signaling induces apoptosis in human myeloma cells in vitro (Catlett-Falcone et al., 1999b) . Taken together, these studies provide further evidence that Stat3 is a valid molecular target for cancer therapy by various methods including genetic, oligonucleotide and small molecule disruption of STAT signaling.
Conclusions and future directions
Numerous studies provide evidence that a causal relationship exists between aberrant STAT activation and oncogenesis, suggesting that therapeutic modalities designed to disrupt STAT signaling hold considerable promise for prevention and treatment of human cancers. Importantly, many types of tumors, particularly aggressive cancers, are initially refractory to chemotherapy or eventually become resistant to the therapies. Thus, there is an urgent need for identi®ca-tion of new molecular targets that may provide more eective therapeutic responses. One of the mechanisms of tumor cell killing by anticancer agents involves apoptosis. As discussed above, constitutive activation of Stat3 and Stat5 signaling in many cases confers resistance to apoptosis in tumor cells. Thus, tumor cells possessing activated Stat3 or Stat5 are predicted to be resistant to chemotherapeutic modalities that may utilize similar apoptosis pathways. Consequently, in addition to the direct killing of tumor cells, another potential advantage of disrupting STAT signaling in tumors is that inactivation of STATs may sensitize drug-resistant tumor cells to chemotherapeutic agents. Such an approach may potentially reduce side eects associated with conventional, aggressive chemotherapeutic regimens and improve the overall response. Development of selective inhibitors of STAT activation for use in combination therapy with more conventional chemotherapy may be a promising area in the ®eld of novel anticancer therapeutics. Additional clinically important bene®ts from the discovery of the contribution of STAT activation to oncogenesis include development of new diagnostic and prognostic assays based on the molecular STAT pro®le of tumors.
In summary, the preponderance of evidence is consistent with the conclusion that inappropriate activation of STAT signaling contributes to oncogenesis by subverting some of the very same biological processes controlled by STATs in normal cells, namely cell proliferation and survival. This conclusion is further supported by the ®ndings that mutationallyactivated forms of Stat3 and Stat5 are sucient to induce some of the characteristics of transformed cells, and that constitutive activation of Stat3 or Stat5 in the context of oncogenesis regulates the expression of genes known to be involved in cell cycle control and apoptosis. Ongoing studies will likely lead to identi®ca-tion of additional STAT-regulated genes that will provide more insights into the roles of STATs in oncogenesis as well as novel molecular approaches to interrupt STAT signaling pathways for potential cancer therapies.
